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Abstract 
Background: The CHADS2 predicts annual risk of ischaemic stroke in non-valvular atrial 
fibrillation. This systematic review and meta-analysis aims to determine the predictive value 
of CHADS2.  
Methods: The literature was systematically searched from 2001 to October 2010. Data was 
pooled and analysed using discrimination and calibration statistical measures, using a 
random effects model.     
Results: Eight data sets (n=2815) were included. The diagnostic accuracy suggested a cut-
point of ≥1 has higher sensitivity (92%) than specificity (12%) and a cut-point of ≥4 has 
higher specificity (96%) than sensitivity (33%). Lower summary estimates were observed for 
cut-points ≥2 (sensitivity 79%, specificity 42%) and ≥3 (specificity 77%, sensitivity 50%). 
There was insufficient data to analyse cut-points ≥5 or ≥6. Moderate pooled c statistic 
values were identified for the classic (0.63, 95% CI 0.52-0.75) and revised (0.60, 95% CI 
0.43-0.72) view of stratification of the CHADS2. Calibration analysis indicated no significant 
difference between the predicted and observed strokes across the three risk strata for the 
classic or revised view. All results were associated with high heterogeneity and conclusions 
should be made cautiously.  
Conclusions: The pooled c statistic and calibration analysis suggests minimal clinical utility of 
both the classic and revised view of the CHADS2 in predicting ischaemic stroke across all risk 
strata. Due to high heterogeneity across studies and low event rates across all risk strata, 
the results should be interpreted cautiously. Further validation of CHADS2 should perhaps 
be undertaken, given the methodological differences between many of the available 
validation studies and the original CHADS2 derivation study. 
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What is known about this topic 
• The CHADS2 clinical prediction rule (CPR) is used to predict the annual stroke risk for 
patients with non-valvular atrial fibrillation.  
• Patients can be stratified according to their stroke risk into low, moderate or high 
risk groups, depending on how many risk factors they have. However, no consensus 
exists as to where the cut-off points for each strata should be. 
• Although the CHADS2 score has previously been validated, there exist 
methodological differences between many of these validation studies and the 
original CHADS2 derivation study.  
What this paper adds 
• This systematic review and meta-analysis validates the CHADS2 score, whilst 
accounting for the methodological differences between the derivation and validation 
studies. Specifically, the current study controls for stroke type and adjusts for the net 
clinical benefit of treatment. 
• This paper compares the predictive ability of two different stratification classification 
methods, the classic view versus the revised view, using both discrimination and 
calibration statistical methods. 
• Overall, the pooled data suggests only reasonable utility of the classic and revised 
view of the CHADS2 score in predicting ischaemic stroke. However, caution should be 
applied when interpreting the results due to high heterogeneity across studies and 
low event rates across all risk strata.  
• Further validation of the CHADS2 score is necessary, given the methodological 
differences between many of the derivation and validation studies.   
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Introduction 
Non-valvular atrial fibrillation (NVAF) is the most common cardiac arrhythmia. Its prevalence 
is age-dependent rising from 1% in patients under 60 years to 15% in those over 85 years. 
(1) The presence of NVAF increases the risk of stroke more than four-fold and approximately 
one third of all strokes are associated with atrial fibrillation. (2, 3) The CHADS2  score is 
commonly used by clinicians to predict the annual stroke risk in patients with NVAF. The 
score was derived by expert consensus and consists of risk factors that were found to 
increase the risk of ischaemic stroke in patients with NVAF in the Atrial Fibrillation 
Investigators (AFI) and Stroke Prevention in Atrial Fibrillation (SPAF) trials. (4) It was tested 
in a non-warfarin population and the risk scores were adjusted for the impact of aspirin 
therapy. It consists of six clinical features and assigns one point for each of congestive heart 
failure, hypertension, age ≥ 75, and diabetes mellitus, and two points for prior history of 
stroke or transient ischaemic attack (TIA). (4) The original CPR forms a cumulative risk score 
for each patient based on the number of risk factors present. Total scores range from 0 to 6 
and annual stroke rate for each of the seven categories range from 1.9 (score 0) to 18.2 
(score 6) (rates adjusted for treatment effect). The CPR can be used to stratify patients 
according to low, moderate and high risk of stroke according to either a classic or a revised 
view of stratification (see Table 1 for summary). The classic view defines low risk by a 
CHADS2 score of 0, moderate risk by a score of 1-2 and high risk as a score of 3-6. The 
revised view defines low risk by a CHADS2 score of 0, moderate risk by a score of 1 and high 
risk as a score of 2-6. 
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A number of studies validating the CHADS2 score have been published. However, there are 
methodological differences between many of these validation studies and the original study 
in which the CPR was derived and validated. Firstly, many studies have not restricted the 
outcome to ischaemic stroke and include non-central nervous system emboli and 
haemorrhagic stroke, resulting in an overestimation of the ischaemic stroke rate. (5) 
Secondly, a number of the validation studies are criticised due to being conducted in treated 
populations. (6) As such, there is limited validation of the original CHADS2 for non-treated 
populations.   
 
This systematic review aims to determine the accuracy of the CHADS2 in predicting 
ischaemic stroke in patients with NVAF across three risk strata (low, moderate, and high) 
according to both the classic and revised view of stratification. The study focuses on one 
stroke type, ischaemic stroke, ICD 9 CM code:434, and excludes all other types of stroke 
such as transient ischaemic attack, haemorrhagic stroke and non-central nervous system 
emboli. Due to the unethical nature of withholding treatment from patients, there exists 
limited placebo data. As such, each of the studies included in the current work contain 
patients receiving oral anticoagulation or antiplatelet therapy, with the observed numbers 
of strokes in each study risk-adjusted for the corresponding treatment benefits. 
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Methods 
Search strategy 
A search string was developed to search the Medline database using the PubMed search 
engine to identify NVAF (‘atrial fibrillation’), stroke (‘cerebrovascular accident’, ‘cerebral 
infarction’, ‘cva’, ‘venous thromboembolism’) and the CHADS2 score (‘CHADS2’, ‘CHADS 2’) 
and type of study (‘prognosis’, ‘indicators’, ‘risks’). The search string was restricted to 
humans and certain publication types were removed (editorial, letter, case reports, 
comments, dictionary or news). No restrictions were placed on language. The search period 
ranged from January 2001 to October 2010 (as the CHADS2 was published in 2001). The 
Cochrane Library, EMBASE, Cinahl and MEDION databases were searched in a similar 
manner. The references of each relevant article were searched. Where necessary, authors 
of published studies were contacted to request additional data.  
 
Study selection 
Inclusion criteria for the systematic review were: (1) Patient population: adult patients with 
a diagnosis of NVAF (including chronic, paroxysmal, persistent, permanent and new onset); 
(2) Outcome measure: ischaemic stroke (ICD-9-CM code 434); (3) Study design: prospective 
or retrospective cohort; (4) Treatment: either warfarin (adjusted dose) or aspirin prescribed 
alone; (5) Explanatory variables: CHADS2 score and; (6) Setting of care: primary care, 
hospital, other specialist settings. Exclusion criteria included: (1) studies that included 
patients with rheumatic/valvular heart disease and other patients in specific populations 
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(e.g. patients undergoing ablation procedures); (2) studies that could not separate all 
ischaemic strokes from other forms of stroke/emboli including transient ischaemic attack, 
haemorrhagic stroke and non-cerebral emboli; (3) studies where the end point was focused 
on mortality; (4) studies that prescribed treatment other than warfarin or aspirin or that 
prescribed combinations of these treatments.    
 
Data extraction 
The titles and abstracts for each article retrieved by the electronic search were 
independently screened by two researchers (EW and CK). The full text article was retrieved 
for any study that was considered potentially relevant. Each full text article was 
independently read and considered for inclusion by two researchers (CK and CD). 
Disagreements were resolved by a third reviewer (EW). Additional data was requested from 
the authors where necessary. For each study, data was extracted for each of the inclusion 
criteria variables.  
 
Quality assessment 
Quality assessment was independently performed by two researchers (CK and CD) following 
the methodological standards reported by McGinn for validation studies of CPRs. (7) This 
quality checklist comprises of five questions that assess the internal and external validity of 
studies. 
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Statistical methods  
Diagnostic accuracy of the CHADS2 score  
The diagnostic accuracy of the CHADS2 at different cut-points was assessed. Data was 
extracted and 2x2 tables were constructed for each cut-point. For example, the cut-point of 
≥1 was constructed by comparing the data below the cut-point (score 0-1) with all data 
above the cut point (score 2-6). Results are presented as summary sensitivities and 
specificities and corresponding 95% confidence intervals, calculated using a random effect 
bivariate model (Stata package metandi). This method accounts for variation in study size 
and heterogeneity beyond chance as a result of clinical and methodological differences 
between the studies. (8) Pooled estimates can only be calculated using this model with four 
or more studies. 
 
The individual and summary estimates of sensitivity and specificity for each cut-point was 
plotted in a summary receiver operating characteristics (sROC) plot, with the associated 
sensitivity (true positive) on the y axis against 1-specificity (false negative) on the x axis. 
Results of interest are the 95% confidence region (which illustrates the precision with which 
pooled values are estimated) and the 95% prediction region (which illustrates the amount 
of between study variation) were plotted around the pooled estimates. Heterogeneity was 
assessed visually (using the sROC plots) and statistically (using the variance of logit 
transformed sensitivity and specificity), where smaller values indicate less heterogeneity 
across studies.    
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As all of the data included in the current study consists of patients treated with either 
warfarin or aspirin, the observed stroke rates were adjusted for the net benefit of 
protection against stroke by each treatment. Warfarin is associated with an overall risk 
reduction of 68% (95% CI, 50 to 79), (9) while aspirin is associated with an overall risk 
reduction of 21% (95% CI, 0 to 38). (10) Therefore, the observed number of strokes in each 
included study in the current work was increased by 68% or 21%, depending on the 
treatment received by each study population.   
 
Predictive value of the CHADS2 score  
The predictive value of both the classic and revised view of stratification of the 
CHADS2 score was measured using the c statistic, to determine if either method of 
classification performed significantly better than chance. A c statistic score of 0.5 or above 
indicates that the classification method performs significantly better than chance. The c 
statistic for both the classic and revised view of the CHADS2 score was calculated for each 
individual data set to allow for direct comparison between the two views of stratification. 
The individual c statistics were then pooled for each of the classic and revised view of 
stratification. The observed stroke rates were adjusted for the net benefit of protection 
offered by warfarin or aspirin treatment, as described above.  
 
Calibration of the CHADS2 score  
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The data presented in the original CHADS2 study was used as the predictive model. (4) The 
data observed in each of the validation data sets was compared against this. The number of 
strokes predicted by the CHADS2 score and those observed within each data set were 
derived across three risk strata – low, moderate and high according to both the classic and 
revised view of stratification of the CHADS2 score. To calculate the predicted stroke risk for 
each of the validation data sets, we applied the adjusted stroke rate from the original 
CHADS2 study for the classic view (low: 1.9; moderate: 3.4; high 11.3) and the revised view 
(low: 1.9; moderate: 2.8; high: 9.8) (see Table 1). The observed stroke rates were adjusted 
for the net benefit of protection offered by warfarin or aspirin treatment, as described 
above.    
 
Results are presented as risk ratios (RR) with 95% confidence intervals for each of the three 
risk strata for both the classic and revised view. A RR <1 indicates that the CHADS2 score 
under-predicts the risk of stroke (i.e. the predicted number of strokes is less than the 
observed number of strokes). A RR >1 indicates that the CHADS2 score over-predicts the risk 
of stroke (i.e. the predicted number of strokes is greater than the observed number of 
strokes). A RR=1 indicates a perfect calibration between the observed and predicted 
number of strokes. Review Manager 5 software from the Cochrane collaboration was used 
to perform the statistical analyses. Risk ratios were calculated using the Mantel-Haenzel 
statistical method. A random effects analysis was performed and heterogeneity was 
described by the I
2
 statistic, where lower values indicate less heterogeneity.               
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Results 
Overview of included studies 
An overview of the search strategy is presented in Figure 1. The initial search retrieved 3145 
articles, of which 3060 were excluded on the basis of their title or abstract. Of the remaining 
85 studies, 60 were excluded as not relevant. Of the remaining 25 articles, one study met all 
the inclusion criteria. The remaining articles were identified as potentially having relevant 
data. For example, the published study may have combined both ischaemic and 
haemorrhagic stroke data but met all other inclusion criteria. In these cases, the authors of 
the remaining articles were contacted. Relevant data was received from four authors. The 
authors from the remaining studies either (1) responded to say that they could not provide 
us with the relevant data or (2) did not respond. The five studies resulted in a total of eight 
sets of data (i.e. three studies provided information for two individual treatment groups).  
 
Study description 
Table 2 summarises the characteristics of the included studies. All five publications were in 
English. The data from only one study had been previously published. (11) Additional data 
was provided by four authors because the data published in the original articles contained 
both ischaemic and non-ischaemic stroke types. (12-15) Two studies collected data 
prospectively, (11, 15) and three retrospectively. (12-14) Data was obtained from different 
settings including primary care, (13) outpatient (11) and specialist settings,(15) as well as 
established databases. (12, 14) Different types of NVAF were included, including chronic,(12, 
13) paroxysmal, (11, 14) persistent, (14) permanent (14, 15) and new onset. (11, 14) Annual 
This article is not an exact copy of the original published article in Thrombosis and Haemostasis. The definitive publisher-
authenticated version of Keogh C, Wallace E, Dillon C, Dimitrov BD, Fahey T. Validation of the CHADS2 clinical prediction rule 
to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost, 2011 Aug 31:106(3):528-38. Epub 2011 
Jul 28 is available online at: http://www.schattauer.de/en/magazine/subject-areas/journals-a-z/thrombosis-and-
haemostasis/contents/archive/issue/1439/manuscript/16384.html 
13 
 
stroke data was available for four data sets (i.e. two studies), (13, 14) with the remaining 
four data sets (i.e. three studies) (11, 12, 15) adjusted for follow-up to derive annual stroke 
data. (16) A total of 2815 participants are included in the analysis. Of these, 2558 
participants were receiving warfarin and 257 were receiving aspirin. A detailed description 
of the number of patients and number of ischaemic strokes observed in each study for each 
of the three risk strata for both the classic and the revised view is presented in Table 3. The 
low risk category (CHADS2 score 0 for both the classic and revised view) has a low number of 
events relative to the moderate and high risk categories. When the data is classified 
according to the classic view, the majority of patients are classified as moderate risk (low 
20.39%; moderate 60.46%; high 19.15%). However, when the data is classified according to 
the revised view, the majority of patients are classified as high risk (low 21.54%; moderate 
33.21%; high 45.25%).         
 
Study quality 
The methodological quality of the studies is presented in Figure 2. The external validity was 
mixed. Although the studies generally represented a wide spectrum of the disease, the 
patients were generally not selected in an unbiased fashion. Similarly, mixed results were 
reported in terms of internal validity. The follow-up of patients was adequate. However, 
issues relating to blinding were generally unreported.  
 
Diagnostic test accuracy of the CHADS2 score 
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The sensitivity, specificity and associated transformed variance of logit are presented in 
Table 4. Cut-points are assessed from CHADS2 ≥1 through CHADS2 ≥4. There was insufficient 
data to complete this analysis for scores ≥5 or ≥6. The results indicate that an increase in 
CHADS2 score is associated with an increased specificity and decreased sensitivity. A cut-
point of ≥1 is associated with a higher sensitivity (92%) than specificity (12%), suggesting 
that this is useful for ruling out the likelihood of stroke when a CHADS2 score of ≥1 is absent 
(i.e. a CHADS2 score of 0). A cut-point of ≥4 is associated with a higher specificity (96%) than 
sensitivity (33%) suggesting that a CHADS2 score of 4 or more is useful for ruling in the 
likelihood of stroke. Lower summary estimates were observed for a cut-point of ≥2 and ≥3. 
A cut-point of ≥2 (i.e. a CHADS2 score of 0 or 1) is associated with higher sensitivity (79%) 
than specificity (42%), suggesting that this is better for ruling out stroke when a score of ≥2 
is absent (i.e. a CHADS2 score of 0 or 1), while a cut-point of ≥3 is associated with higher 
specificity (77%) than sensitivity (50%) suggesting that a CHADS2 score of 4 or more is 
better at ruling in a stroke. However, there is wide heterogeneity associated with each of 
the cut-points as indicated by the visual inspection of the confidence and prediction ellipse 
around the mean (see on-line version) and statistically by the variance of logit transformed 
sensitivity and specificity (Table 4).   
 
Predictive value of the CHADS2 score 
The predictive value of the CHADS2 score for both the classic and revised view of 
classification for each individual study is presented in Table 5. The c statistic indicates wide 
variability across studies in the predictive value of both the classic and revised views of 
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stratification. For the classic view, the c statistic ranges from poor predictability (0.44, 95% 
CI 0.17-0.70) to good predictability and performing better than chance (0.79, 95% CI 0.76-
0.82). A similar pattern emerged for the revised view, with the c statistic ranging from 0.43 
(0.22-0.65) to 0.75 (0.73-0.78). For two studies, the classic view resulted in a higher c 
statistic than the revised view and for three studies the opposite pattern was true. However, 
in general similar c statistic values were reported for both the classic and revised view 
within each individual study, with the majority of values indicating that the CPR performed 
at or around the level of chance.  
 
The c statistic values were pooled for the classic and revised views. The results indicate that 
both the classic (0.63, 95% CI 0.52-0.75) and revised (0.60, 95% CI 0.43-0.72) views of 
stratification offered limited predictability, with the classic view performing slightly better 
than chance, and less so for the revised view of the CHADS2 score. The pooled analysis for 
the c statistic values indicated high levels of heterogeneity. This should be considered when 
interpreting the results.        
 
Calibration of annual ischaemic stroke risk  
The pooled estimates indicate that there is good calibration between the predicted and 
observed events in each of the CHADS2 score risk strata, for both the classic and revised 
view (Fig. 3). However, these results should be interpreted with caution as visual inspection 
of the forest plots coupled with the I
2
 values (ranging from 33% to 88%) suggest high levels 
of heterogeneity.   
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In an attempt to account for the heterogeneity, a subgroup analysis based on prevalence 
was conducted for each of the three risk strata for the classic and revised views. Prevalence 
of stroke in each validation data set ranged from 0% to 22.5%. A study was classified as high 
prevalence if the associated prevalence was higher than that reported by the 
CHADS2 original study (4.9%). Four data sets were classified as high prevalence and the 
remaining four were classified as low prevalence. Overall, the subgroup analysis reduced the 
heterogeneity, with most risk strata associated with low heterogeneity. The pooled 
estimates suggest that the calibration for the high prevalence group for both the classic and 
revised view remained unchanged relative to the original analysis. The pooled estimates 
from the low prevalence group suggest that the CHADS2 score over predicts the risk of 
stroke in the moderate (RR 5.27, 95%CI 1.54-18.02) and high (RR 3.97, 95%CI 1.35-11.85) 
risk categories for the classic view of stratification for the CHADS2 score and for the 
moderate risk category with the revised view of the CHADS2 score, although the confidence 
intervals were very wide and included 1.0 (RR 2.72, 95%CI 0.50-14.62). Once again, these 
results should be interpreted with caution due to the small number of studies in each 
prevalence group and the wide confidence intervals around the pooled estimates.  
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Discussion  
Summary of results 
The diagnostic test accuracy analysis of the different cut-points produced mixed results in 
terms of the strength of the observations. A cut-point of ≥1 (i.e. a CHADS2 score of 0) or ≥2 
(i.e. a CHADS2 score of 0 or 1) is useful for ruling out the likelihood of stroke when absent 
and a cut-point of ≥3 or ≥4 is useful for ruling in the likelihood of stroke when present. 
However, only the cut-points of ≥1 and ≥4 were associated with high summary estimate 
values. There was insufficient data to calculate a score for a cut-point of either ≥5 or ≥6. The 
pooled analysis of the c statistic values indicates that both the classic and revised views of 
stratification offer limited predictability. The pooled analysis from the calibration of the 
CHADS2 score suggests good calibration for both the classic and revised view of 
stratification. The results from all of these analyses should be judged in the context of high 
heterogeneity and low event rates across all risk strata.   
 
The classic view of stratification of the CHADS2 score classified the majority of patients as 
moderate risk, while the revised view of stratification classified the majority of patients as 
high risk. Quality assessment of the internal and external validity of the included studies 
produced mixed results.  
 
Strengths and weaknesses  
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The strengths include: the restriction of stroke type to only one type of stroke (ischaemic 
stroke); adjusting for the net benefit of protection offered with warfarin or aspirin; 
comparing the utility of the classic and revised view of risk stratification models; the 
inclusion of original data from authors; the inclusion of real-world, non-trial data; and 
pooling the results of studies to conduct a formal quantitative validation of the 
CHADS2 score.  
 
We acknowledge that our review has several limitations. There is modest to high 
heterogeneity across the studies included in this review. This was problematic for the 
diagnostic test accuracy, as well as the validation of the CHADS2 score. Heterogeneity can be 
caused by a number of factors including chance, variation in the pre-test probability of 
having an ischaemic stroke and other factors. However, the current study controlled for one 
potential source of heterogeneity in the calibration element of the study by conducting a 
sub-group analysis according to the prevalence of ischaemic strokes in each data set.  
 
A further potential source of heterogeneity is the variability in the intensity of 
anticoagulation across the individual studies. Research indicates that patients outside the 
therapeutic INR range are at an increased risk of thrombotic events, with patients in a sub-
therapeutic INR range associated with more frequent and more severe strokes. (17, 18) In 
the current work, some studies failed to report the achieved international normalised ratio 
(INR) levels, (12, 15) whilst another study reported variation in acceptable INR levels for 
different age groups within the study. (14) This may potentially introduce some bias in 
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terms of the number of strokes occurring in each study. There is insufficient data in the 
current study to perform a subgroup analysis in this regard. Nevertheless, intensity of 
anticoagulation should be considered in all future meta-analyses in this area.        
 
Only five studies (eight data sets) were included in the current study. This figure does not 
reflect the large number of papers that have been published on the CHADS2 score, which 
may bias the results. However, as outlined in the introduction, there are a number of 
methodological disparities across these validation studies. The current study has attempted 
to limit the impact of this type of heterogeneity by restricting the stroke type to ischaemic 
stroke only (excluding transient ischaemic attacks, haemorrhagic strokes and all other non-
central nervous system emboli). We view this as an advantage to the current work, which is 
designed to test the validity of the CHADS2 score in predicting ischaemic stroke.  
 
The pooled calibration method of analysis used to pool the data sets in the validation of the 
CHADS2 score is based on a comparative approach previously reported in a single validation 
study. (19) The current method extends this method and employs the absolute risk from the 
derivation study as a model to generate predicted values in multiple validation studies. The 
absolute risk is presented according to the relevant risk strata of the CPR so that the clinical 
value of the CPR according to these strata can be assessed.       
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One potential limitation is the need to adjust for the net benefit of protection offered by 
warfarin or aspirin in each of the data sets included. Limited placebo data exist in patients 
with NVAF and current treatment guidelines recommend that all patients with NVAF be 
provided with some form of antithrombotic therapy. (20, 21) As a result, it was necessary to 
adjust for the treatment effect according to the risk reduction offered by warfarin and 
aspirin. This value does not account for the variation associated with the upper and lower 
confidence intervals.       
 
It was not possible to determine the diagnostic accuracy of a cut-point of ≥5 or ≥6 in the 
current study due to insufficient data. As such, caution should be applied when interpreting 
these results to prevent the incorrect assumption that a lack of data equates to a lack of 
evidence to support the clinical validity of these cut-points.  
 
There was wide variability across studies for the c statistic analysis. This may result from 
methodological differences, including differences between study populations so that c-
statistics from one study cannot necessarily be directly compared to that derived from a 
different study. The results from the pooled c statistic values reported here are lower than 
the original CHADS2 study. (4) However, the lower values are consistent with more recent 
literature and this is attributed to a change in the risk factor profile in current patient 
populations. (22)  
 
Implications for practice  
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The results from the diagnostic accuracy suggest that two cut-points are helpful in terms of 
clinical decision making. A cut-point of ≥1 is associated with high sensitivity and is useful for 
ruling out the likelihood of stroke when a CHADS2 score of ≥1 is absent (i.e. a CHADS2 score 
of 0). A cut-point of ≥4 (i.e. a CHADS2 score of 4, 5 or 6) is associated with high specificity 
and is therefore useful for ruling in the likelihood of stroke. The results indicate that cut-
points of ≥2 and ≥3 were associated with relatively lower levels of sensitivities and 
specificities. It is not possible to comment on the clinical validity of individual cut-points of 
≥5 or ≥6 as there was insufficient data available for analysis. Clinicians should therefore not 
score out the utility of an individual CHADS2 score of 5 or 6 in predicting stroke.  
 
The pooled results from the calibration of the CHADS2 score suggest that is a good predictor 
of ischaemic stroke risk in people with NVAF across all three risk strata of low, moderate 
and high risk, particularly in high prevalence populations. The revised view of the risk strata 
(low 0; moderate 1; and high 2-6) offers marginally better prediction than the classic view 
(low 0; moderate 1-2; and high 3-6). The revised view of classification is helpful in terms of 
therapeutic decision making as it results in more people being classified as high risk and 
fewer patients classified as moderate risk. This means that more patients (i.e. those in the 
high risk stratum) will receive with a clear recommendation for anticoagulation therapy and 
fewer patients (i.e. those in the moderate risk stratum) will receive an ambiguous 
recommendation for either antiplatelet or anticoagulation therapy. However, high 
heterogeneity between studies was observed for both the discrimination and calibration 
analyses. Therefore, results should be interpreted cautiously.  
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Future research 
Different risk factors are associated with different incidence of stroke. (23, 24) Prior history 
of stroke or TIA is a strongly weighted risk factor in the CHADS2 score and is associated with 
a total of 2 points, double that of other risk factors. However, a CHADS2 score of 2 may be 
comprised of this single risk factor or may be comprised of two individual risk factors 
associated with 1 point (e.g. age and hypertension). Without individual patient level data it 
is not possible to test for this in the current study. This suggests one avenue for future 
research.   
 
The current study offered a comparison between the predictive ability of the classic and 
revised view of risk stratification for the CHADS2 score. However, the CHADS2 score is only 
one of a number of CPRs that have been developed to predict stroke in patients with atrial 
fibrillation. This remains a potential source of confusion for the clinician in terms of selecting 
the optimal CPR to predict stroke in this population. Future research should validate the 
performance of individual CPRs across different studies and data sets, as well as compare 
different rules within the same data set. Furthermore, each of these CPRs should undergo 
formal impact analysis to determine if their application impacts physician behaviour or 
changes patient outcomes.   
 
Recent European guidelines have recommended against artificially stratifying patients into 
low, moderate and high stroke risk strata. (25) Instead, these guidelines suggest a risk 
factor-based approach to inform recommendations for antithrombotic therapy. The 
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CHA2DS2-VASc (a modified version of the CHADS2 score) offers one such approach. (6) 
Research suggests that the CHA2DS2-VASc accurately identifies those patients with atrial 
fibrillation who are truly at low risk of thromboembolism. (24) This is particularly important 
given that recent data suggests that new and safer anticoagulation drugs could now be 
offered at a substantially lower risk of ischaemic stroke (>0.9% per year). (26) Therefore, it is 
necessary to be able to accurately discriminate between those patients who are truly low 
risk and do not need antithrombotic therapy and those with one or more risk factors that 
would benefit from oral anticoagulation.       
            
Conclusion  
The pooled c statistic and calibration analysis suggests minimal clinical utility of both the 
classic and revised view of the CHADS2 score in predicting ischaemic stroke across all risk 
strata. Due to high heterogeneity across studies and low event rates across all risk strata, 
the results presented here should be interpreted cautiously. Further validation of 
CHADS2 score should perhaps be undertaken, given the methodological differences 
between many of the available validation studies and the original CHADS2 derivation study. 
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Legends to Figures and Tables 
Figure 1: Overview of search strategy. This is an overview of the number of articles included 
during each stage of the systematic review process.  
Figure 2: Methodological quality of studies included in the review (McGinn Criteria). This 
provides an overview of the methodological quality of the final set of articles included in the 
systematic review and meta-analysis. The methodological quality criteria concern both 
internal and external validity.  
Figure 3: Results from classic view [low (0), moderate (1-2) and high (3-6)] and revised 
view [moderate (1) and high (2-6)] of the CHADS2 score. This provides a graphical 
representation of the calibration of the CHADS2 score. A RR <1 indicates that the CHADS2 
score under-predicts the risk of stroke. A RR >1 indicates that the CHADS2 score over-
predicts the risk of stroke. A RR=1 indicates a perfect calibration between the observed and 
predicted number of strokes. 
ON-LINE FIGURE: Summary receiver operating characteristics (sROC) plots for each cut-off 
point of the CHADS2 CPR* This provides a graphical view of pooled estimates for each of the 
cut-points of the CHADS2 score. The 95% confidence region and 95% prediction region 
illustrate the precision with which pooled values are estimated and to illustrate the amount 
of between study variation, respectively.      
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Table 1: Summary of the CHADS2 clinical prediction rule stratified according to low, 
moderate and high risk (associated stroke rate). This provides a detailed overview of the 
different stroke risk stratification schemes, the classic view and the revised view. Details 
included are the associated CHADS2 score, stroke rate and treatment recommendations.  
Table 2: Characteristics of studies included in the review. This provides specific details for 
each of the data sets from each study included in the final systematic review and meta-
analysis. 
Table 3: Number of patients, number of ischaemic strokes and proportion of total sample 
categorised as low, moderate and high risk for each included study for both the classic and 
revised view of the CHADS2 score at one year follow-up. This provides details on the 
number of patients and number of ischaemic strokes observed in each study for each of the 
three risk strata for both the classic and the revised view. Total number of patients and the 
representative percentage of overall number of patients for low, moderate and high risk 
group for both the classic and revised view of stratification is also presented.   
Table 4: Summary estimates of sensitivity and specificity for the CHADS2 score. This 
provides details of the sensitivity and specificity and associated variance logit results for 
each of the individual CHADS2 score cut-points ≥1 through ≥4. There was insufficient data to 
calculate values for a cut-point of ≥5 or ≥6.  
Table 5: Predictive value of the CHADS2 score for the classic and revised view of 
stratification measured using the c statistic (95% confidence intervals). This presents the c 
statistic for each of the individual studies, as well as the overall pooled estimate c statistic. 
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Table 1: Summary of the CHADS2 clinical prediction rule stratified according to low, 
moderate and high risk (associated stroke rate) 
Risk stratification Low risk Moderate risk High risk 
Classic view: CHADS2 score 0 1-2 3-6 
          Associated stroke rate 1.9 3.4* 11.3* 
Revised view: CHADS2 score 0 1 2-6 
          Associated stroke rate 1.9 2.8 9.8* 
Guideline recommendations (20, 21) Antiplatelet 
treatment 
Antiplatelet 
treatment  or 
anticoagulation†
 
Anticoagulation 
recommended 
Note: CHADS2 score forms a cumulative score based on six clinical features. 1 point for each of 
congestive heart failure, hypertension, age ≥ 75, and diabetes mellitus and 2 points for prior history 
of stroke or transient ischaemic attack (TIA) 
* Rates are the mean of the original probability intervals reported by Gage (4) 
 † Choice of treatment depends on physician and patient preferences 
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Table 2: Characteristics of studies included in the review 
Authors Study setting Study type Participants Type of 
NVAF* 
Treatment 
received 
Outcome 
event 
Duration of 
follow-up 
Published 
Data 
Boccuzzi 2009 (12) 
(warfarin) 
Medical and pharmacy 
claims database; USA 
Retrospective 
cohort 
N=1724 Chronic Warfarin 
(adjusted dose) 
Ischaemic 
stroke 
Mean = 12.94 
months 
No  
Jacobs 2009 (13) 
(warfarin) 
Geriatric ambulatory, 
urban primary care 
practice; USA  
Retrospective 
cohort  
N=90 Chronic (≥3 
months) 
Warfarin: 
adjusted dose 
Ischaemic 
Stroke 
1 year No 
Jacobs 2009 (13) 
(aspirin) 
Geriatric ambulatory, 
urban primary care 
practice; USA 
Retrospective 
cohort  
N=16 Chronic (≥3 
months) 
Aspirin Ischaemic 
stroke 
1 year No 
Masaki et al 2009 
(11) (warfarin) 
Outpatient clinic; Japan Prospective 
cohort 
N=182 Paroxysmal Warfarin: 
adjusted dose 
(Average 
INR†=1.89 ±0.31) 
Cerebral 
infarction 
Average = 703
±88 days  
Yes 
Guo 2010 (14) 
(warfarin) 
Clinical information 
systems database; China 
Retrospective 
cohort 
N=6 Paroxysmal, 
persistent, 
Warfarin: 
adjusted dose. 
Ischaemic 
stroke 
1 year No 
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permanent 
and new 
onset   
Target INR was 
2.0 (range 1.6-
2.5) but in those 
>80 years INR 
1.5-1.8 accepted 
Guo 2010 (14) 
(aspirin) 
Clinical information 
systems database; China 
Retrospective 
cohort 
N=42 Paroxysmal, 
persistent, 
permanent 
and new 
onset   
Aspirin  Ischaemic 
stroke 
1 year No 
Ruitz Ortiz 2010 
(15) (Warfarin)  
Outpatient cardiology 
clinics at University 
hospitals; Spain 
Prospective 
cohort 
N=556 Permanent  Warfarin: 
Adjusted dose. 
Target INR 2-3 
Ischaemic 
stroke 
Mean=2.4 
years 
No 
Ruitz Ortiz 2010 
(15) (Aspirin) 
Outpatient cardiology 
clinics at University 
hospitals; Spain 
Prospective 
cohort 
N=199 Permanent  Aspirin Ischaemic 
stroke 
Mean=2.4 
years 
No  
*NVAF=non-valvular atrial fibrillation †INR= international normalised ratio 
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Table 3: Number of patients, number of ischaemic strokes and proportion of total sample categorised as low, moderate and high risk for 
each included study for both the classic and revised view of the CHADS2 score at one year follow-up 
Study Classic view 
 
Revised view 
 Low Moderate High Low Moderate High 
N ischaemic strokes*/N patients 
 
Boccuzzi 2009 (12)  
(warfarin)** 
9/449 81/1047 121/228 9/449 34/624 168/651 
Jacobs 2009(13) 
(warfarin) 
0/1 3/41 3/48 0/1 0/12 6/77 
Jacobs 2009 (13) 
(aspirin) 
 
0/1 0/9 0/6 0/1 0/4 0/11 
Masaki 2009 
(11)(warfarin)** 
3/32 16/106 22/44 3/32 Unable to compile† Unable to compile† 
Guo 2010 (14) 
(warfarin) 
 
0/0 0/0 0/6 0/0 0/0 0/6 
Guo 2010 (14) 
(aspirin)** 
 
0/2 4/20 3/20 0/2 1/10 5/30 
Ruiz Ortiz 2010 (15) 
(warfarin)** 
 
3/42 2/363 3/115 3/42 1/189 5/325 
Ruiz Ortiz 2010 (15) 
(aspirin) 
1/47 1/116 1/36 1/47 1/46 3/106 
Total events/total N 16/574 107/1702 153/539 161/574 37/885 187/1206 
% of total population 
in each strata 
20.39% 60.46% 19.15% 20.39% 33.21% 45.25% 
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*The number of strokes is adjusted for the net benefit of protection offered by warfarin or aspirin treatment. ** The data is adjusted for 
follow-up to derive annual stroke data †Unable to compile as the published data was originally presented as stratified according to the classic 
view scoring system.   
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Table 4: Summary estimates of sensitivity and specificity for the CHADS2 score* 
CHADS2 score No. of studies Sensitivity 
(95% CI) 
Variance logit 
(sensitivity) 
Specificity 
(95%  CI) 
Variance logit 
(specificity) 
≥1 6 0.92 
(0.82-0.96) 
0.31 0.12 
(0.06-0.24) 
0.85 
≥2 4 0.79 
(0.64-0.89) 
0.01 
 
0.42  
(0.24-0.63) 
0.74 
≥3 6 0.50 
(0.37-0.63) 
0.88 0.77  
(0.59-0.88) 
0.99 
≥4 5 0.33  
(0.21-0.47) 
0.00 0.96 
(0.66-0.10) 
7.28 
*There was insufficient data to examine the CHADS2 score for ≥5 or ≥6 
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Table 5: Predictive value of the CHADS2 score for the classic and revised view of 
stratification measured using the c statistic (95% confidence intervals)* 
Study Classic view 
c statistic (95% confidence 
interval) 
Revised view 
c statistic (95% confidence 
interval) 
Boccuzzi 2009 (12) (warfarin) 0.79 (0.76-0.82) 0.75 (0.73-0.78) 
Guo 2010 (14) (aspirin) 0.53 (0.32-0.74) 0.57 (0.40-0.75) 
Guo 2010 (14) (warfarin) Insufficient data Insufficient data 
Jacobs 2009 (13) (aspirin) Insufficient data Insufficient data 
Jacobs 2009 (13) (warfarin) 0.49 (0.26-0.71) 0.58 (0.54-0.62) 
Masaki 2009 (11) (warfarin) 0.71 (0.62-0.79) Data not available in this format 
Ruiz Ortiz 2010 (15) (aspirin) 0.52 (0.07-0.97) 0.54 (0.28-0.79) 
Ruiz Ortiz 2010 (15) (warfarin) 0.44 (0.17-0.70) 0.43 (0.22-0.65) 
Pooled analysis  0.63 (0.52-0.75) 0.60 (0.43-0.72) 
*The c statistic is calculated based on the number of strokes that have been adjusted for the 
net benefit of protection offered by warfarin or aspirin treatment. 
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Figure 1: Overview of search strategy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Records retrieved from 
search of databases (n=3427) 
Records after duplicates 
removed (n=3145) 
Records screened (n=3145) 
Full-text articles assessed for 
eligibility (n=85) 
Records excluded (n=3060) 
Full-text articles excluded as not relevant 
(n=60) 
• CHADS2 score not discussed (n=17) 
• No data presented (review article) 
(n=8) 
• CHADS2 not used to predict 
ischaemic stroke (n=19) 
• CHADS2 used in specific 
populations (n=14) 
• Articles with duplicate data (n=2) 
Articles that met all inclusion 
criteria (n=1) 
Articles with potentially 
relevant data* (n=24) 
Articles included in analysis 
(n=5) 
Data sets included in analysis 
(n=8) 
Studies in which authors 
contacted (n=24) 
Authors who responded with  
relevant data (n=4) 
* These studies were selected on the basis that the author may have been able to provide data (e.g. 
data analysed in published paper included ischaemic stroke combined with haemorrhagic stroke) 
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Figure 2: Methodological quality of studies included in the review (McGinn Criteria) 
 
 
 
 
  
0 1 2 3 4 5
Q1
Q2
Q3
Q4
Q5
Yes No Unreported
Q1 (External validity): Do patients represent a wide spectrum of severity of disease? 
Q2 (External validity): Were patients selected in an unbiased fashion? 
Q3 (Internal validity): Was there >80% follow-up of those enrolled? 
Q4 (Internal validity): Were those assessing the presence of predictors blinded to the    outcome event? 
Q5 (Internal validity): Were those assessing the outcome event blinded to the presence of predictors?  
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Figure 3: Results from classic view [low (0), moderate (1-2) and high (3-6)] and revised 
view [moderate (1) and high (2-6)] of the CHADS2 score
Study or Subgroup
7.1.1 Classic view: Low risk
Boccuzzi 2009 (warfarin)
Guo 2010 (aspirin)
Guo 2010 (warfarin)
Jacobs 2009 (aspirin)
Jacobs 2009 (warfarin)
Masaki 2009 (warfarin)
Ruiz Ortiz 2010 (aspirin)
Ruiz Ortiz 2010(warfarin)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.45, df = 3 (P = 0.69); I² = 0%
Test for overall effect: Z = 0.67 (P = 0.51)
7.1.2 Classic view: Moderate risk
Boccuzzi 2009 (warfarin)
Guo 2010 (aspirin)
Guo 2010 (warfarin)
Jacobs 2009 (aspirin)
Jacobs 2009 (warfarin)
Masaki 2009 (warfarin)
Ruiz Ortiz 2010 (aspirin)
Ruiz Ortiz 2010(warfarin)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 1.23; Chi² = 18.77, df = 5 (P = 0.002); I² = 73%
Test for overall effect: Z = 0.72 (P = 0.47)
7.1.3 Classic view: High risk
Boccuzzi 2009 (warfarin)
Guo 2010 (aspirin)
Guo 2010 (warfarin)
Jacobs 2009 (aspirin)
Jacobs 2009 (warfarin)
Masaki 2009 (warfarin)
Ruiz Ortiz 2010 (aspirin)
Ruiz Ortiz 2010(warfarin)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 1.81; Chi² = 35.30, df = 5 (P < 0.00001); I² = 86%
Test for overall effect: Z = 0.57 (P = 0.57)
7.1.4 Revised view: Moderate risk
Boccuzzi 2009 (warfarin)
Guo 2010 (aspirin)
Guo 2010 (warfarin)
Jacobs 2009 (aspirin)
Jacobs 2009 (warfarin)
Ruiz Ortiz 2010 (aspirin)
Ruiz Ortiz 2010(warfarin)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.47; Chi² = 4.50, df = 3 (P = 0.21); I² = 33%
Test for overall effect: Z = 0.37 (P = 0.71)
7.1.5 Revised view: High risk
Boccuzzi 2009 (warfarin)
Guo 2010 (aspirin)
Guo 2010 (warfarin)
Jacobs 2009 (aspirin)
Jacobs 2009 (warfarin)
Ruiz Ortiz 2010 (aspirin)
Ruiz Ortiz 2010(warfarin)
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 2.11; Chi² = 42.95, df = 5 (P < 0.00001); I² = 88%
Test for overall effect: Z = 0.10 (P = 0.92)
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On-line version: Summary receiver operating characteristics (sROC) plots for each cut-off 
point of the CHADS2 score*   
                              
 
 
*There was insufficient data to complete this analysis for ≥5 or ≥6 
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